Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tanox initiates early stage trial of asthma treatment
TNX-650 has a mechanism of action unique from currently available asthma treatments and has the potential to be a therapeutic option for patients whose disease is not currently
TNX-650 has a mechanism of action unique from currently available asthma treatments and has the potential to be a therapeutic option for patients whose disease is not currently
In December 2005, Wyeth and Progenics entered into a collaboration to develop methylnaltrexone. Under the terms of the agreement, Progenics has the potential to receive as much as
<p>The injunction has been granted prior to a final court decision on the validity of the patent. <br /><br />The preliminary injunction will be in effect until the
The new Nexium formulation is an oral suspension product and will be an alternative to Nexium tablets. This new oral suspension version of Nexium contains esomeprazole, the same
Upon completion of the transaction of its biotech businesses, Cambrex said that it will concentrate on deploying its resources to maximize the potential of its human health business
The research could be significant for the treatment of Crohn's disease as Tysabri may be alternative to the anti-TNF class as patients remain in remission over a long
The objectives of this trial are to assess the safety, tolerability, pharmacokinetic profile and antiviral activity of HCV-796. The trial will asses HCV-796 when used in combination with
MD Anderson joins the University of Vermont and Scott & White Memorial Hospital in the trial which began treating patients in May 2006. MD Anderson has joined research
Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process. Wyeth will continue to use Affymetrix microarray technology
PRX-07034 is a highly selective 5-HT6 receptor antagonist being developed for the treatment of obesity, as well as for cognitive impairment associated with Alzheimer's disease and schizophrenia. “We